Advanced

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.

Parnetti, L; Chiasserini, D; Andreasson, Ulrika; Ohlson Andersson, Maria LU ; Hüls, C; Zetterberg, H; Minthon, Lennart LU ; Wallin, Anne; Andreasen, N and Talesa, V N, et al. (2011) In Acta Neurologica Scandinavica 124. p.122-129
Abstract
Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin ÅK, Andreasen N, Talesa VN, Blennow K. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2010.01435.x. © 2010 John Wiley & Sons A/S. Objectives - To measure cerebrospinal fluid (CSF) activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in patients with Alzheimer's disease (AD) participating in randomized clinical trials from three European centers, before and after long-term treatment with different AChE inhibitors (AChEIs). Materials and methods - Of the 144 patients included in the study, 104 were treated... (More)
Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin ÅK, Andreasen N, Talesa VN, Blennow K. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2010.01435.x. © 2010 John Wiley & Sons A/S. Objectives - To measure cerebrospinal fluid (CSF) activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in patients with Alzheimer's disease (AD) participating in randomized clinical trials from three European centers, before and after long-term treatment with different AChE inhibitors (AChEIs). Materials and methods - Of the 144 patients included in the study, 104 were treated with donepezil, 15 with galantamine, 16 with rivastigmine, and nine with placebo. CSF AChE and BChE activities were measured at baseline and after 1- year treatment. Results - Donepezil and galantamine groups showed a significant increase in CSF AChE activity at follow-up, while no changes for BChE activity were observed; in donepezil group, a positive correlation between plasma concentration and AChE activity was documented. Conversely, in rivastigmine group, a decrease in CSF activity of both enzymes was observed. CSF AChE and BChE activities were not correlated with the clinical outcome in any group considered. CSF biomarkers did not show any change after treatment. Conclusions - AChEIs differently influence the activity of target enzymes in CSF independent of their pharmacodynamic effects. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Neurologica Scandinavica
volume
124
pages
122 - 129
publisher
Wiley-Blackwell
external identifiers
  • WOS:000292519900007
  • PMID:20880294
  • Scopus:79960146040
ISSN
1600-0404
DOI
10.1111/j.1600-0404.2010.01435.x
language
English
LU publication?
yes
id
67ac40f7-100a-4c89-896c-8d99fd8737a5 (old id 1711622)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20880294?dopt=Abstract
date added to LUP
2010-11-03 16:21:46
date last changed
2016-10-30 04:35:21
@misc{67ac40f7-100a-4c89-896c-8d99fd8737a5,
  abstract     = {Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin ÅK, Andreasen N, Talesa VN, Blennow K. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2010.01435.x. © 2010 John Wiley & Sons A/S. Objectives - To measure cerebrospinal fluid (CSF) activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in patients with Alzheimer's disease (AD) participating in randomized clinical trials from three European centers, before and after long-term treatment with different AChE inhibitors (AChEIs). Materials and methods - Of the 144 patients included in the study, 104 were treated with donepezil, 15 with galantamine, 16 with rivastigmine, and nine with placebo. CSF AChE and BChE activities were measured at baseline and after 1- year treatment. Results - Donepezil and galantamine groups showed a significant increase in CSF AChE activity at follow-up, while no changes for BChE activity were observed; in donepezil group, a positive correlation between plasma concentration and AChE activity was documented. Conversely, in rivastigmine group, a decrease in CSF activity of both enzymes was observed. CSF AChE and BChE activities were not correlated with the clinical outcome in any group considered. CSF biomarkers did not show any change after treatment. Conclusions - AChEIs differently influence the activity of target enzymes in CSF independent of their pharmacodynamic effects.},
  author       = {Parnetti, L and Chiasserini, D and Andreasson, Ulrika and Ohlson Andersson, Maria and Hüls, C and Zetterberg, H and Minthon, Lennart and Wallin, Anne and Andreasen, N and Talesa, V N and Blennow, Kristina},
  issn         = {1600-0404},
  language     = {eng},
  pages        = {122--129},
  publisher    = {ARRAY(0xca921b0)},
  series       = {Acta Neurologica Scandinavica},
  title        = {Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.},
  url          = {http://dx.doi.org/10.1111/j.1600-0404.2010.01435.x},
  volume       = {124},
  year         = {2011},
}